| Literature DB >> 31961568 |
Muhammad Hanif1,2, Samuel M Meier2,3, Zenita Adhireksan4, Helena Henke2, Sanela Martic5, Sanam Movassaghi1, Mahmoud Labib6, Wolfgang Kandioller2,7, Stephen M F Jamieson8, Michaela Hejl2, Michael A Jakupec2,7, Heinz-Bernhard Kraatz9,10, Curt A Davey4,11, Bernhard K Keppler2,7, Christian G Hartinger1,2.
Abstract
Hydroxypyr(id)ones constitute an emerging platform for the design of drug molecules, owing to their favorable biocompatibility and toxicity profiles. Herein, [RuII (η6 -p-cymene)] complexes with 3-hydroxy-2-pyridinone functionalized with morpholine and thiomorpholine, as a means often used in medicinal chemistry to alter the physicochemical properties of drug compounds, are reported. The compounds underwent hydrolysis of the Ru-Cl bond and the aqua species were stable for up to 48 h in aqueous solution, as observed by 1 H NMR spectroscopy and ESI-MS. The compounds formed adducts with amino acids and proteins through cleavage of the pyridinone ligand. Binding experiments to the nucleosome core particle by means of X-ray crystallography revealed similar reactivity and exclusive binding to histidine moieties of the histone proteins. Preliminary cyclin-dependent kinase 2 (CDK2)/cyclin A kinase inhibitory studies revealed promising activity similar to that of structurally related organometallic compounds.Entities:
Keywords: antitumor agents; bioorganometallic chemistry; medicinal chemistry; ruthenium; synthesis design
Year: 2017 PMID: 31961568 DOI: 10.1002/cplu.201700050
Source DB: PubMed Journal: Chempluschem ISSN: 2192-6506 Impact factor: 2.863